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ABSTRACT
Objective CT quantification of aortic valve calcification 
(CT- AVC) is useful in the assessment of aortic stenosis 
severity. Our objective was to assess its ability to 
track aortic stenosis progression compared with 
echocardiography.
Methods Subjects were recruited in two cohorts: (1) a 
reproducibility cohort where patients underwent repeat 
CT- AVC or echocardiography within 4 weeks and (2) a 
disease progression cohort where patients underwent 
annual CT- AVC and/or echocardiography. Cohen’s d- 
statistic (d) was computed from the ratio of annualised 
progression and measurement repeatability and used 
to estimate group sizes required to detect annualised 
changes in CT- AVC and echocardiography.
Results A total of 33 (age 71±8) and 81 participants 
(age 72±8) were recruited to the reproducibility and 
progression cohorts, respectively. Ten CT scans (16%) 
were excluded from the progression cohort due to non- 
diagnostic image quality. Scan- rescan reproducibility was 
excellent for CT- AVC (limits of agreement −12% to 10 
%, intraclass correlation (ICC) 0.99), peak velocity (−7% 
to +17%; ICC 0.92) mean gradient (−25% to 27%, ICC 
0.96) and dimensionless index (−11% to +15%; ICC 
0.98). Repeat measurements of aortic valve area (AVA) 
were less reliable (−44% to +28%, ICC 0.85).
CT- AVC progressed by 152 (65–375) AU/year. For 
echocardiography, the median annual change in peak 
velocity was 0.1 (0.0–0.3) m/s/year, mean gradient 2 
(0–4) mm Hg/year and AVA −0.1 (−0.2–0.0) cm2/year. 
Cohen’s d- statistic was more than double for CT- AVC 
(d=3.12) than each echocardiographic measure (peak 
velocity d=0.71 ; mean gradient d=0.66; AVA d=0.59, 
dimensionless index d=1.41).
Conclusion CT- AVC is reproducible and demonstrates 
larger increases over time normalised to measurement 
repeatability compared with echocardiographic measures.
INTRODUCTION
Aortic stenosis represents a major cause of 
morbidity and mortality, the burden of which is set 
to increase. Currently, the only definitive treatment 
is surgical or transcatheter aortic valve replacement 
in patients with severe symptomatic stenosis. Aortic 
valve narrowing progresses inexorably but at a vari-
able and unpredictable rate in individual patients. 
Frequent echocardiographic follow- up is therefore 
mandated to determine the optimal timing for 
intervention.1
The clinical assessment of aortic stenosis severity 
is based on two- dimensional echocardiography 
and Doppler, with measurement of the peak jet 
velocity, mean gradient and aortic valve area (AVA) 
frequently used to guide severity assessment.1 
However, the measurement of disease progression 
by echocardiography is challenged by small changes 
in these markers of haemodynamic severity over 
time, combined with a relatively high degree of 
variability between measurements.2 3 A comple-
mentary imaging technique capable of providing 
improved reproducibility and sensitivity to change 
is therefore desirable. This is of importance in the 
clinical setting for accurate tracking of disease 
progression, and also in the research arena, where 
imaging end points are increasingly being used 
to assess the effects of novel therapies on aortic 
stenosis progression.
Quantification of aortic valve calcification by 
non- contrast CT (CT- AVC) has demonstrated 
promise in accurately defining the valvular calcifi-
cation burden, with sex- specific thresholds demon-
strating good diagnostic accuracy compared with 
concordant echocardiography and providing incre-
mental prognostic information.4 5 In this study, our 
objective was to assess the ability of CT- AVC to 
monitor aortic stenosis progression compared with 
echocardiographic assessments. We investigated 
scan- rescan reproducibility and annual progression 
of both CT- AVC and echocardiographic measure-




Participants aged >50 years attending the outpa-
tient Department of the Edinburgh Heart Centre 
with aortic stenosis (peak aortic jet velocity >2 
m/s) were recruited into two cohorts as part of a 
previously reported study (NCT01358513) and 
an ongoing clinical trial (NCT02132026).6 7 In 
the reproducibility cohort, participants underwent 
repeat echocardiography or CT- AVC scanning 
within 4 weeks. In the disease progression cohort, 
participants underwent either repeat echocardiog-
raphy, CT or both after at least 1 year. This research 
was undertaken without patient involvement. 
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Patients were not invited to comment on the study design and 
were not consulted to interpret the results or contribute to 
writing or editing of this document for readability or accuracy.
Baseline assessment
All participants underwent a comprehensive baseline clinical 
assessment. Echocardiography was performed by an experienced 
echocardiographer (AW) using a prespecified protocol according 
to the European Society of Echocardiography guidelines8 on the 
same scanner of a British Society of Echocardiography accred-
ited laboratory. Multiple acoustic windows were assessed with 
the S51 and D2cwc probes (Philips Medical Systems, The Neth-
erlands). Aortic stenosis severity was assessed on the basis of the 
peak velocity, mean gradient, AVA (calculated using the conti-
nuity equation) and dimensionless index (DI; defined as left 
ventricular outflow tract (LVOT) peak velocity divided by aortic 
peak velocity) according to the American Heart Association and 
American College of Cardiology guidelines.9
To measure CT- AVC, an ECG- gated non- contrast CT scan was 
performed during inspiration on a 128 multidetector scanner 
(Biograph mCT Siemens, 40 mA/rot tube voltage 100 kV, tube 
current selected using automatic exposure control).10 In the 
absence of contraindications, participants were administered 
beta-­blockade­to­achieve­a­resting­heart­rate­≤65­bpm.­Images­
were reconstructed in the axial plane with 3 mm slice width and 
1.5 mm increment. Valvular calcification was quantified by the 
Agatston method11 using dedicated analysis software (Vitrea 
Advanced, Vital Images, Minnetonka, USA; online supplemental 
figure 1). Care was taken to exclude calcium from extravalvular 
structures such as the mitral valve annulus and coronary arteries. 
When confluent calcium extended into the ascending aorta, the 
origin of the left coronary artery was set as the most rostral slice 
beyond which further calcium was excluded.4 12 The aortic valve 
calcium burden was expressed as CT- AVC in Agatston Units 
(AU).
Scan-rescan reproducibility
The reproducibility cohort consisted of two groups of partici-
pants with aortic stenosis who underwent either repeat CT- AVC 
scoring or echocardiographic assessment of their valve. In 
one group, CT was performed at baseline and again within 4 
weeks. Scan- rescan reproducibility was determined for CT- AVC 
measurements. In a second group, patients underwent two echo-
cardiographic assessments during the same visit, using the same 
scanner on the same bed and in the same room by two accredited 
echocardiographers (AW, JA) blinded to each other’s assessment. 
Scan- rescan reproducibility was determined for haemodynamic 
measures of stenosis severity (peak velocity, mean gradient, AVA 
and DI).
Assessment of disease progression
Participants in the disease progression cohort returned for repeat 
clinical assessment and echocardiography at 1 and 2 years as 
well as repeat CT at either 1 or 2 years.13 The same scanner and 
imaging protocol was used for all CT scans and echocardiograms 
were performed by the same echocardiographer (AW) using the 
same scanner. To assess disease progression, annualised differ-
ences in each measure of stenosis severity were calculated. In 
participants who underwent three echocardiograms (baseline, 1 
and 2 years), a line of best fit was used to determine annualised 
progression. Finally, Cohen’s d- statistic (d) was calculated for 
CT- AVC and each echocardiographic assessment (peak velocity, 
mean gradient, AVA, DI) to express the magnitude of progression 
normalised by the uncertainty in the measurement technique. 
This was calculated by dividing the magnitude of the annualised 
progression­by­the­measurement­repeatability,­defined­as­(1/√2)­
of the SD of the differences between measurements at scan and 
rescan within the reproducibility cohort.14
Group size analysis
Power analysis was performed to determine group sizes needed 
to detect changes in CT- AVC and echocardiographic parame-
ters in a hypothetical clinical trial. To determine the group size 
needed to detect changes after a therapeutic intervention in a 
single group, power analyses were based on paired t- tests. The 
annualised progression and measurement repeatability for each 
modality were used to compute the effect size and subsequently 
group sizes required to detect i) disease progression using 
CT- AVC and each echocardiography measure and ii) sample 
sizes needed to detect treatment effects on disease progression 
using the different modalities. Treatment effects of 30%, 20% 
and 10% of the annualised progression values measured in the 
progression group were considered. Group sizes were estimated 
for powers of 70%, 80% and 90% and an error probability (α) 
of 0.05. Analysis was carried out using G- power software.15
Statistical methods
Continuous variables were expressed as either mean±SD or 
median (IQR) depending on normality. Parametric (unpaired 
Student’s t- test) and non- parametric (Mann- Whitney U) tests 
were used for independent variables as appropriate. Categorical 
data were presented as n (%) and compared when appropriate 
using a contingency table and Fisher’s or χ2 tests. Reproduc-
ibility was assessed using Bland- Altman analysis and intraclass 
correlation (ICC). Correlation between continuous variables 
was assessed with linear regression analysis and either Pearson’s 
r or Spearman’s Rho subject to normality. Annualised rates of 
progression were calculated using the difference between two 
time- points (CT- AVC) or regression analysis over three time- 




Thirty- three participants comprised the reproducibility cohort 
(aged 71±8, 68% male). Eighteen participants underwent two 
echocardiograms (aged 70±8, 67% male, table 1) and 15 under-
went two CT scans (aged 73±7, 67% male, table 1). A total of 
81 participants were enrolled in the disease progression cohort 
(aged 72%±8%, 69% male, table 1). Of these, 71 underwent 
repeat echocardiography and 61 underwent repeat CT- AVC. Ten 
CT scans were excluded due to suboptimal image quality, leaving 
51 included in the analysis. There was a high prevalence of 
cardiovascular risk factors, with the majority of patients having 
co- existing hypertension.
Reproducibility cohort
Within the reproducibility cohort (n=33), 15 patients under-
went two non- contrast ECG- gated CT scans within 19 (IQR 
14–28 days, range 7–98 days). Scan- rescan reproducibility for 
CT- AVC was excellent, without fixed or proportional bias (mean 
difference­ −1%­ (limits­ of­ agreement­ −12%­ to­ 10%),­ ICC­
0.99; table 2, figure 1). Measurement variability for CT- AVC 
was 49 AU, or 4.2% when normalised to the median CT- AVC 
at baseline. Intraobserver (median CT- AVC 1178 AU, mean 
difference­ 1%­ (limits­ of­ agreement­ 9%­ to­−11%),­ ICC­0.99)­
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and interobserver (median CT- AVC 1207 AU, mean difference 
0%­(limits­of­agreement­−5%­to­6%),­ICC­0.99)­reproducibil-
ities were also excellent. Scan- rescan reproducibility was also 
assessed with two different observers and demonstrated good 
reproducibility (ICC 1.00 (95% CI 0.99 to 1.00), mean differ-
ence­2.57%­(44­AU)­and­limits­of­agreement­−27.5%­to­22.4%)­
(online supplemental figure S2).
Eighteen patients underwent two transthoracic echocardio-
grams during a single study visit. Scan- rescan reproducibility 
was excellent for peak velocity (mean difference 5%; limits of 
agreement­−7%­to­17%;­ICC­0.96;­measurement­repeatability­
4.0%;­ ICC­ 0.96)­ and­ DI­ (mean­ difference­ −1.7%;­ limits­ of­
agreement­−11.1%­to­14.5%;­ICC­0.98;­measurement­repeat-
ability 3.3%). Reproducibility was also good for mean gradient 
(mean­difference­1%;­limits­of­agreement­−25%­to­27%;­ICC­




AVC and aortic stenosis severity
At baseline, CT- AVC correlated with all echocardiographic 
measures (online supplemental table S1). The closest associa-
tions were observed with peak velocity (r=0.75 (95% CI 0.63 
to 0.84), p<0.001) and mean gradient (r=0.75 (95% CI 0.64 to 
0.83),­p<0.001)­and­the­weakest­with­AVA­(r=−0.46­(95%­CI­
−0.61­to­−0.25),­p<0.001).










Number 18 15 81 71 51
Age (years) 70±8 73±7 72±8 72±8.2 73±7
Male 12 (67) 10 (67) 55 (69) 50 (70) 34 (67)
Body mass index (kg/m2) 30±4 30±6 29±5 28±4 28±4
Systolic blood pressure (mm Hg) 152±20 151±18 146±20 144±18 143±17
Comorbidity
  Diabetes mellitus 4 (22) 4 (27) 15 (18) 13 (18) 9 (18)
  Hypertension 13 (72) 11 (73) 60 (74) 50 (70) 36 (70)
  Documented CAD 9 (50) 6 (40) 33 (41) 31 (44) 26 (51)
  Current smoker 8 (44) 6 (40) 9 (11) 8 (11) 5 (9)
  Serum creatinine (mg/dL) 0.89±0.23 0.70±0.11 1.01±0.31 1.00±0.30 0.98±0.28
Medications
  ACE inhibitors 8 (44) 6 (40) 32 (40) 27 (38) 20 (39)
  AIIRB 4 (22) 3 (20) 11 (13) 9 (13) 7 (13)
  Beta- blockers 7 (39) 7 (47) 33 (41) 30 (43) 23 (45)
  Statins 14 (78) 9 (60) 54 (66) 46 (64) 34 (67)
Baseline echocardiographic assessment
  AV jet velocity (m/s) 3.5 (3.2–4.0) 3.3 (3.0–3.8) 3.4 (2.8–4.1) 3.3 (2.7–3.9) 3.0 (2.5–3.6)
  AV mean gradient (mm Hg) 25 (21–31) 24 (22–30) 25 (16–36) 24 (14–32) 21 (13–25)
  AV area (cm2) 1.1 (0.8–1.3) 1.1 (1.0–1.3) 1.1 (0.9–1.4) 1.2 (0.9–1.5) 1.2 (1.0–1.5)
  Dimensionless index 0.30 (0.23–0.37) 0.32 (0.25–0.40) 0.32 (0.25–0.39) 0.33 (0.26–0.39) 0.36 (0.30–0.40)
CT assessment
  AV calcium score (AU) 989 (497–1708) 1178 (579–2109) 1339 (553–2422) 1190 (505–2182) 874 (459–1792)
Mean±SD, median (IQR) and number (percentage).
AIIRB, angiotensin 2 receptor antagonists; AS, aortic stenosis; AU, Agatson Units; AVA, aortic valve area; CAD, coronary artery disease; LV, left ventricle; LVH, left ventricular 
hypertrophy.
Table 2 Reproducibility of CT- AVC and echocardiography assessments of aortic stenosis severity
Bias, %
(95% limits of agreement)
Bias, units






  Scan- scan reproducibility, AU −1 (−12–10) −20 (69) 49 (4.2%) 0.99 (0.99 to 1.00)
  Intraobserver reproducibility, AU −1 (−11–7) −12 (85) – 1.00 (1.00 to 1.00)
  Interobserver reproducibility, AU 0 (−5–6) 11 (65) – 0.99 (0.99 to 1.00)
Echocardiography, scan- rescan
  AV max, m/s 5 (−7–17) 0.17 (0.20) 0.14 (4.0%) 0.96 (0.78 to 0.99)
  Mean gradient, mm Hg 1 (−25–27) 0.28 (4.3) 3.0 (12.0%) 0.97 (0.91 to 0.99)
  AVA (VTI), cm2 −8 (−44–28) −0.11 (0.24) 0.17 (15.5%) 0.85 (0.59 to 0.94)
  Dimensionless index −2 (−11–15) 0.01 (0.02) 0.01 (3.3%) 0.98 (0.95 to 0.99)
AU, Agatson Units; AVA, aortic valve area; CT- AVC, CT quantification of aortic valve calcification; VTI, velocity time integral.
 on M











1909Doris MK, et al. Heart 2020;106:1906–1913. doi:10.1136/heartjnl-2020-317125
Valvular heart disease
Patient follow-up
During the 2- year follow- up period (736 (IQR 722–760) days), 
61 participants (75%) underwent repeat CT (13 at 1 year and 
48 at 2 years). Images were non- interpretable in 10 participants 
(16%) due to motion artefact and were excluded, predominantly 
in those in whom beta- blockers were contraindicated. Follow- up 
echocardiography was performed in 71 participants at 1 year 
and 62 at 2 years. No echocardiography scans were excluded 
from analysis.
Aortic stenosis disease progression
Across all patients, modest progression in each echocardio-
graphic­measure­of­severity­was­observed­(Δ­peak­velocity­0.12­
(IQR­0.0–0.25)­m/s/year;­Δ­mean­gradient­2.0­(IQR­0.0–4.0)­mm­
Hg/year;­Δ­AVA­−0.11­ (IQR­−0.26–0.02),­ Δ­DI­−0.02­ (IQR­
−0.04­ to­−0.01))­ (table 3). When patients were divided into 
mild, moderate and severe aortic stenosis, those in the moderate 
group demonstrated the clearest evidence of disease progression 
(n=30,­Δ­peak­velocity­0.18­(IQR­0.06–0.30)­m/s/year;­Δ­mean­
gradient 3.2 (IQR 0.7–5.4) mm Hg/year) (table 3).
Across the cohort as a whole, CT- AVC progressed by 152 
(IQR 65–375) AU/year, with the most rapid rates of progres-
sion­ observed­ in­ participants­ with­ the­most­ severe­ disease­ (Δ­
CT- AVC; mild AS 64 (IQR 48–134) AU/year, moderate AS 289 
(IQR 106–443) AU/year, severe AS 342 (IQR 163–583) AU/year) 
(table 3, figure 2).
The Cohen’s d- statistic (d) was calculated by dividing the 
overall annualised rate of change in each severity measure by 
the measurement repeatability (table 3) By this method, CT- AVC 
displayed a greater progression to measurement repeatability 
ratio (CT- AVC: d=3.12) when compared with each echocar-
diographic parameter (peak velocity: d=0.71; mean gradient: 
d=0.66; AVA: d=0.59; DI d=1.41). When patients with more 
advanced disease were considered, the differences between 
echocardiography and CT- AVC were greater. In participants 
with severe aortic stenosis, CT- AVC displayed a greater than 
sixfold higher value (d=6.98) compared with echocardiographic 
measures (peak velocity d=0.71; mean gradient d=1.0; AVA 
d=0.0; DI d=0.71). In those with moderate and mild disease, 
the d- statistic for CT- AVC remained higher when compared 
with echocardiographic measures of the same severity (table 3, 
figure 3).
Group size analysis
Using the cohort- averaged progression and measurement repeat-
ability values, the effect size for a matched- pairs t- test was 
computed for CT- AVC and each echocardiographic measure. 
The group size required to detect annualised disease progression 
for CT- AVC was smaller than for echocardiographic measures 
(CT- AVC: 4, peak velocity: 33, mean gradient: 39, AVA: 48 
(α=0.05, power=80%)). Similarly, the group size required to 
detect a treatment effect of a new therapy (30%, 20% and 10% 
reduction in the annualised progression) was >10- fold smaller 
for CT- AVC than for echocardiographic measures (CT- AVC: 20, 
43, 165 patients, respectively; peak velocity: 351, 787, 3142 
patients, respectively; mean gradient: 403, 910, 3632 patients, 
respectively; AVA: 505, 1134, 4516 patients, respectively 
(α=0.05, power=80%)) (figure 4). Group size calculations 
should also consider the proportion of non- interpretable scans 
that may be encountered.
DISCUSSION
In this study, we have investigated the utility of CT- AVC and 
echocardiography in assessing disease progression in patients 
with aortic stenosis. CT- AVC demonstrated excellent scan- 
rescan reproducibility. Calculation of Cohen’s d- statistic demon-
strated that CT- AVC had a large annualised change normalised 
to measurement repeatability compared with echocardiography, 
with a fourfold higher value for CT- AVC (d=3.12) compared 
with peak velocity (d=0.71). (figure 3) CT- AVC may therefore 
be a useful technique both in clinical practice for assessing aortic 
stenosis progression and as an endpoint in clinical trials assessing 
the efficacy of novel therapies.
Given the central role of calcification in the progression of 
aortic stenosis, direct assessments of calcification hold major 
Figure 1 Scan- rescan reproducibility of CT quantification of aortic valve calcification (CT- AVC) and echocardiographic assessment of aortic stenosis 
severity. Bland- Altman plots displaying the scan- rescan reproducibility of aortic stenosis severity measurements on serial CT- AVC (3.9±3.3 weeks) and 
echocardiography (1±0 days). VTI, velocity time integral.
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interest.16 Quantification of aortic valve calcification has demon-
strated considerable promise in a number of studies, discerning 
the presence of severe stenosis among patients with discordant 
echocardiography and providing powerful prognostic informa-
tion.5 17 18 In this study, we have demonstrated excellent scan- 
rescan reproducibility of CT- AVC coupled with relatively large 
progression in values over time, demonstrating the feasibility 
and potential advantages of this modality for tracking aortic 
stenosis progression.
Before an imaging technique can be applied to routine clin-
ical practice, clinicians must be reassured that the technique is 
robust and reproducible. Measurement of CT- AVC is technically 
straightforward, although can be complicated by motion artefact, 
particularly in patients with advanced disease, systolic dysfunc-
tion or conduction disease in whom administration of beta- 
blockade is not possible. In this study, this resulted in exclusion 
of 16% of scans. This limitation of CT- AVC must be considered 
when deciding whether to use this test in the clinical or research 
settings and certain patient characteristics including body mass 
index, tachycardia or contraindications to beta- blockade may be 
used to identify patients in whom CT- AVC may be unreliable. 
However, when CT- AVC is possible we have demonstrated that 
excellent reproducibility can be achieved with a consistent and 
standardised approach. While all echocardiography scans were 
of diagnostic quality in our study, we acknowledge that there is 
a selection bias in our patient population since participants were 
only recruited if they had clear assessments of aortic stenosis 
severity on clinical echocardiograms. In non- selective cohorts, 
it is estimated that 10%–15% of patients have poor echocar-
diographic windows, similar to our observations for CT- AVC. 
Furthermore, variability in echocardiography was minimised 
by performing two echocardiograms under as consistent condi-
tions as possible, thereby diminishing many sources of error 
encountered in clinical practice. This approach necessitated two 
different echocardiographers performing the scan to avoid recall 
bias.
For echocardiography, while peak velocity and mean gradient 
both demonstrated good reproducibility, repeatability of AVA 
was poor, likely reflecting the multiple different measurements 
required for its calculation. Measurement of the LVOT diameter 
represents the major source of error in calculation of AVA. By 
disregarding LVOT diameter and considering a simplified ratio 
of LVOT- to- aortic velocity, the DI overcomes discrepancies in 
LVOT measurements and has proven effective in distinguishing 
aortic stenosis severity and predicting adverse outcomes.19–21 We 
have shown that this measure improves reproducibility when 
compared with AVA.
In order to compare the utility of CT- AVC and echocardiog-
raphy for tracking disease progression, both the magnitude of 
change and measurement repeatability must be considered. On 
Table 3 Disease progression on echocardiography and CT- AVC in patients with aortic stenosis
Variable All patients Mild aortic stenosis Moderate aortic stenosis Severe aortic stenosis
Baseline echocardiography
  No. of patients 81 25 33 23
  Peak aortic jet velocity, (m/s) 3.4 (2.8–4.1) 2.5 (2.4–2.7) 3.4 (3.2–3.7) 4.5 (4.1–5.1)
  Mean gradient
  (mm Hg)
25 (16–36) 13 (11–16) 25 (22–29) 43 (38–58)
  Aortic valve area (cm2) 1.1 (0.9–1.4) 1.4 (1.2–1.7) 1.1 (1.0–1.3) 0.8 (0.6–0.9)
  Dimensionless index 0.32 (0.25–0.39) 0.42 (0.38–0.49) 0.31 (0.28–0.33) 0.21 (0.20–0.25)
Follow- up echocardiography
  No. of patients 71 24 30 17
  Δ aortic jet velocity (m/s/year) 0.1(0.0–0.3) 0.1 (0.0–0.2) 0.2 (0.1–0.3) 0.1 (−0.1–0.2)
  Δ aortic jet velocity (%m/s/year) 3.5 (0.0–7.8) 3.2 (−0.7–6.3) 5.0 (2.3–10.2) 3.2 (−1.1–5.2)
  Cohen’s d- statistic 0.71 0.71 1.43 0.71
  Δ mean gradient
  (mm Hg/year)
2 (0–4) 1 (0–2) 3 (1–5) 3 (0–5)
  Δ mean gradient
  (%mm Hg/year)
9.5 (−0.5–17.0) 7.5 (−2.4–14.9) 11.6 (2.4–29.5) 7.0 (−1.7–13.7)
  Cohen’s d- statistic 0.66 0.33 1.0 1.0
  Δ aortic valve area (cm2/year) −0.1 (−0.2 to 0.0) −0.1 (−0.2 to −0.0) −0.1 (−0.1 to −0.0) 0.0 (−0.1 to −0.0)
  Δ aortic valve area (%cm2/year) −8.7 (−14.4 to −2.9) −5.2 (−13.3 to −0.6) −9.9 (−15.6 to −4.8) −7.7 (−15.0 to 0)
  Cohen’s d- statistic 0.59 0.59 0.59 0.0
  Δ Dimensionless index −0.02 (−0.04 to −0.01) −0.02 (−0.04 to 0.00) −0.02 (−0.04 to −0.01) −0.01 (−0.02 to 0.00)
  Δ Dimensionless index
  (%/year)
−5.7 (−11 to −2.0) −4.4 (10.0 to −0.3) −6.7 (−13.6 to −2.9) −5.7 (−10.3 to 2.3)
  Cohen’s d- statistic 1.41 1.41 1.41 0.71
Baseline CT
  No. of patients 72 23 30 19
  AV calcium score (AU) 1339 (553–2422) 489 (281–693) 1427 (777–2215) 3386 (1770–6211)
Follow- up CT
  No. of patients 51 21 24 6
  Δ AV calcium score (AU/year) 152 (65–375) 64 (48–134) 289 (106–443) 342 (163–583)
  Δ AV calcium score (%AU/year) 20.0 (13.0–24.5) 20.3 (17.5–31.1) 20.0 (10.8–24.5) 16.9 (10.9–24.4)
  Cohen’s d- statistic 3.12 1.30 5.90 6.98
AU, Agatson Units; AV, aortic valve; CT- AVC, CT quantification of aortic valve calcification.
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this basis, we calculated the Cohen’s d- statistic for each modality. 
This indicated that CT- AVC appears superior to echocardiog-
raphy for detecting small changes in disease severity over time. 
Indeed, this marker was four times higher for CT- AVC compared 
with peak velocity. This may have important clinical implications 
when tracking disease progression and predicting when patients 
are likely to require valve intervention. Further research is 
required to assess how this approach may work in clinical prac-
tice, but CT- AVC is likely to be of particular value in patients 
whose heart rate can be optimised for imaging and who have 
poor echocardiographic windows or low flow states where mean 
gradient and peak velocity may underestimate disease severity.
Our data also support a role for CT- AVC as an end point 
in research trials investigating the effects of novel therapies. 
Figure 2 Aortic stenosis disease progression measured using CT quantification of aortic valve calcification (CT- AVC) and echocardiography. 
Annualised disease progression across each cohort using CT calcium scoring (A), peak aortic jet velocity (B), mean gradient (C) and aortic valve area 
(D). Relatively large annualised changes in the CT calcium score are observed compared with smaller changes and wide overlap in the measurements 
obtained by echocardiography. Dashed lines demonstrate the expected measurement repeatability from scan- rescan measurements.
Figure 3 CT calcium scoring and echocardiography to monitor disease progression in aortic stenosis. CT calcium scoring of the aortic valve (AV) 
and echocardiography in a patient at baseline (A–C) and 1 year (D–F). Baseline CT calcium scoring demonstrates CT quantification of aortic valve 
calcification (CT- AVC) of 2372 AU (A), transthoracic echocardiography of the AV shows calcified leaflets with a calcium score of 4 (B) and Doppler 
echocardiography demonstrates a peak velocity of 3.77 m/s (C) at baseline. At 1 year, CT- AVC has increased to 2773 (D), the AV calcium score on 
echocardiography is graded as 4 (E) and the peak jet velocity has increased to 3.95 m/s (F). AVA, aortic valve area; VTI, velocity time integral.
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Imaging end points are increasingly adopted for this purpose, 
and those with greater reproducibility and sensitivity to detect 
small changes in progression are likely to minimise cost and 
sample sizes required (SALTIRE 2 NCT02132026). Indeed, our 
data suggest that >10- fold fewer patients would be required 
to detect 10%, 20% and 30% treatment effects using CT- AVC 
(165, 43 and 20 patients, respectively) compared with peak 
velocity (3142, 787 and 351 patients, respectively). While this 
suggests a considerable advantage in using CT- AVC, consid-
eration should be placed on the frequency of non- diagnostic 
scans and clinical characteristics for which CT- AVC may not be 
suitable. Indeed, the proportion of non- interpretable CT scans 
must be taken into account when considering sample sizes and 
measurement repeatability. It is also important to consider that 
CT- AVC does not account for the effects of therapy on non- 
calcific valve thickening (ie, fibrosis) and echocardiography 
remains the first- line imaging technique to assess aortic stenosis. 
Furthermore, another important consideration is the radiation 
dose associated with CT, although standard imaging techniques 
enable CT calcium scoring to be performed with low levels of 
radiation exposure (1–3 mSV).22
Our study has several limitations. We acknowledge that our 
study numbers are small and in the reproducibility cohort, 
different patients underwent repeat CT- AVC to those under-
going repeat echocardiography. While the characteristics of both 
patient groups were similar, we cannot rule out the possibility 
of confounding variables and recognise this as a limitation of 
our study. Our study findings should therefore be confirmed in 
larger studies with direct comparisons of reproducibility and 
disease progression for echo and CT- AVC within the same popu-
lation. Furthermore, we assessed annualised changes in disease 
severity in all patients who underwent follow- up beyond 1 year. 
This assumes linear disease progression and therefore does not 
take into account a more rapid rise in disease progression as 
severity increases, although this is consistent with other studies 
investigating disease progression in aortic stenosis.23 24
Figure 4 Sample sizes needed for studies of novel therapies in aortic stenosis using CT quantification of aortic valve calcification (CT- AVC) to assess 
their effect on disease progression. The number of participants required in a study to detect a given treatment effect size at different levels of power 
are plotted. For each modality an upper bound at 90% power and lower bound at 70% are plotted with α=0.05 for all. Nominal treatment effects up 
to 50% of the measured annualised progression for each modality are considered. Group size calculations should also consider the proportion of non- 
interpretable scans that may be encountered. AVA, aortic valve area.
Key questions
What is already known on this subject?
 ► Aortic stenosis remains an important cause of morbidity and 
mortality worldwide and its burden is set to increase.
 ► Two- dimensional echocardiography is currently the gold 
standard imaging modality to define and track changes in 
disease severity over time.
 ► CT has recently emerged as a useful modality to quantify 
valvular calcification burden in aortic stenosis and provides 
prognostic information.
What might this study add?
 ► In this study, we have highlighted that measurement of aortic 
valve calcification by CT is reproducible and may be valuable 
in detecting small changes in disease severity over time, 
potentially highlighting patients with more rapid progression 
of aortic stenosis.
How might this impact on clinical practice?
 ► By providing a sensitive measure of disease progression, 
the measurement of aortic valve calcification by CT may be 
useful in both highlighting patients with rapidly progressive 
aortic stenosis and as an end point in clinical trials of novel 
therapies designed to slow disease progression.
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CONCLUSION
CT- AVC is a robust and reproducible imaging technique that 
holds major promise as a method for tracking disease progres-
sion in aortic stenosis.
Twitter Michelle Claire Williams @imagingmedsci and Marc R Dweck @MarcDweck
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